You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
瑞普生物(300119.SZ): 犬、貓用鎮靜止痛產品瑞美靜獲批
格隆匯 03-16 16:56

格隆匯3月16日丨瑞普生物(300119.SZ)公佈,根據《獸藥管理條例》和《獸藥註冊辦法》的規定,公司全資子公司瑞普(天津)生物藥業有限公司生產的犬、貓用鎮靜止痛產品近日通過國家比對文號評價審核,獲得了由農業農村部核發的獸藥產品批准文號。商品名稱:瑞美靜;獸藥通用名稱:鹽酸右美託咪定注射液;規格:10ml:5mg;批准文號:獸藥字020033309;有效期:2023年3月3至202832日。

瑞美靜(鹽酸右美託咪定注射液)是一種高特異的α2-腎上腺素受體興奮藥,可降低交感神經的活性,用於犬、貓臨牀檢查和治療時鎮靜和止痛,同時對其他中樞抑制劑(如麻醉劑)具有顯著的增效作用,可用於犬深度麻醉前的前驅鎮靜。瑞美靜具有起效快、易甦醒、呼吸抑制率低、配伍禁忌少、適用範圍廣、增效且提高手術安全性等優勢,可通過靜脈、肌內兩種途徑給藥,提高臨牀使用的便捷性。

瑞美靜是我國第一個通過比對文號評價並獲批的圍手術期寵物用鎮靜止痛藥,打破原研公司在我國長達12年的壟斷,實現了進口替代,可與公司現有產品易弗寧(異氟烷)、美喜康(美洛昔康片)形成前驅鎮靜→維持麻醉→術後鎮痛的圍手術期全套產品組合,為寵物醫生開展手術提供極大便利。該產品批准文號的取得有助於提升公司在寵物醫療行業的整體競爭力,將為公司帶來新的業績增長點。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account